Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acitretin + etanercept
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
The combination of **acitretin + etanercept** is used as a dual therapy for moderate to severe chronic plaque psoriasis. Acitretin is a retinoid and acts as a small molecule modulator of gene transcription involved in cell differentiation and proliferation. Etanercept is a biologic agent, specifically a fusion protein that blocks tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. This combination aims to increase the efficacy of psoriasis treatment while allowing lower dosages of each drug, potentially reducing side effects of monotherapy. Clinical trials have shown that this regimen can be as effective as higher-dose etanercept monotherapy and more effective than acitretin alone, with a similar safety profile[1][2][3][4].
- Brand names
- EnbrelSoriataneSoriatane CK
- Other names
- etanercept + acitretin
02
Targets
RARA (Retinoic acid receptor alpha)RXRA (Retinoid X receptor alpha)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on acitretin + etanercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acitretin + etanercept.